About instil bio inc - TIL
Instil Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
TIL At a Glance
Instil Bio, Inc.
3963 Maple Avenue
Dallas, Texas 75219
| Phone | 1-972-499-3350 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -71,372,000.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TIL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.655 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.57 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.036 |
TIL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,198,352.941 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TIL Liquidity
| Current Ratio | 39.527 |
| Quick Ratio | 39.527 |
| Cash Ratio | 15.754 |
TIL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -30.344 |
| Return on Equity | -50.386 |
| Return on Total Capital | -35.857 |
| Return on Invested Capital | -31.489 |
TIL Capital Structure
| Total Debt to Total Equity | 74.805 |
| Total Debt to Total Capital | 42.794 |
| Total Debt to Total Assets | 41.417 |
| Long-Term Debt to Equity | 74.479 |
| Long-Term Debt to Total Capital | 42.607 |